儿童急性淋巴细胞白血病无颅脑放疗下的中枢神经系统控制改善:St Jude Total Therapy 16
St Jude Total Therapy 16 研究纳入 598 例 0 至 18 岁新发急性淋巴细胞白血病患儿,采用风险导向化疗且不做预防性颅脑放疗。结果显示 5 年无事件生存率 88.2%、总生存率 94.1%,任何中枢神经系统复发累积风险 1.5%;高剂量 PEG-门冬酰胺酶未改善结局,而早期诱导额外鞘内治疗与高危患儿中枢复发改善相关且未增加癫痫或感染风险。
要点
- 无预防性颅脑放疗下 5 年任何中枢神经系统复发累积风险为 1.5%。
- 高剂量 PEG-门冬酰胺酶(3,500 U/m2)未改善治疗结局。
- 早期诱导额外鞘内治疗与高危患儿中枢复发降低相关且未增加毒性。
核心结论
- 提高 PEG-门冬酰胺酶剂量未能改善结局,但早期诱导期额外鞘内治疗可能有助于改善高危患儿的中枢神经系统控制且不增加过度毒性。
研究设计与样本
- 2007 至 2017 年连续纳入 598 例 0 至 18 岁患儿,接受风险导向化疗且不做预防性颅脑放疗,并随机接受 PEG-门冬酰胺酶 3,500 U/m2 或常规 2,500 U/m2。
主要发现
- 598 例患儿 5 年无事件生存率为 88.2%(95% CI,84.9% 至 91.5%),总生存率为 94.1%(95% CI,91.7% 至 96.5%)。
- 任何孤立或合并中枢神经系统复发的累积风险为 1.5%(95% CI,0.5% 至 2.5%)。
- T 细胞表型是任何中枢神经系统复发的唯一独立危险因素(风险比 5.15;95% CI,1.3 至 20.6;P = .021)。
- 359 例具有中枢复发高危特征患儿 5 年任何中枢复发率为 1.8%(95% CI,0.4% 至 3.3%),显著低于既往 Total Therapy 15 中 248 例相同特征患儿的 5.7%(95% CI,2.8% 至 8.6%)(P = .008)。
- 接受与未接受额外两剂鞘内治疗的患者在诱导期癫痫或感染的累积风险上无显著差异。
关键数值与推荐
- PEG-门冬酰胺酶随机剂量为 3,500 U/m2 对比常规 2,500 U/m2。
- 具有中枢复发增加风险特征的患者在缓解诱导前 2 周接受额外两剂鞘内治疗。
临床怎么用
- 对于具有中枢复发高危特征的儿童急性淋巴细胞白血病患者,可考虑在早期诱导期增加鞘内治疗以改善中枢神经系统控制。
- 不推荐以提高 PEG-门冬酰胺酶剂量至 3,500 U/m2 作为改善结局的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Despite contemporary treatment, up to 10% of children with acute lymphoblastic leukemia still experience relapse. We evaluated whether a higher dosage of PEG-asparaginase and early intensification of triple intrathecal therapy would improve systemic and CNS control. PATIENTS AND METHODS: Between 2007 and 2017, 598 consecutive patients age 0 to 18 years received risk-directed chemotherapy without prophylactic cranial irradiation in the St Jude Total Therapy Study 16. Patients were randomly assigned to receive PEG-asparaginase 3,500 U/m2 versus the conventional 2,500 U/m2. Patients presenting features that were associated with increased risk of CNS relapse received two extra doses of intrathecal therapy during the first 2 weeks of remission induction. RESULTS: The 5-year event-free survival and overall survival rates for the 598 patients were 88.2% (95% CI, 84.9% to 91.5%) and 94.1% (95% CI, 91.7% to 96.5%), respectively. Cumulative risk of any-isolated or combined-CNS relapse was 1.5% (95% CI, 0.5% to 2.5%). Higher doses of PEG-asparaginase did not affect treatment outcome. T-cell phenotype was the only independent risk factor for any CNS relapse (hazard ratio, 5.15; 95% CI, 1.3 to 20.6; P = . 021). Among 359 patients with features that were associated with increased risk for CNS relapse, the 5-year rate of any CNS relapse was significantly lower than that among 248 patients with the same features treated in the previous Total Therapy Study 15 (1.8% [95% CI, 0.4% to 3.3%] v 5.7% [95% CI, 2.8% to 8.6%]; P = .008). There were no significant differences in the cumulative risk of seizure or infection during induction between patients who did or did not receive the two extra doses of intrathecal treatment. CONCLUSION: Higher doses of PEG-asparaginase failed to improve outcome, but additional intrathecal therapy during early induction seemed to contribute to improved CNS control without excessive toxicity for high-risk patients.
引用
- Jeha S, Pei D, Choi J, et al. Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. J Clin Oncol. 2019. PMID: 31657981. doi:10.1200/JCO.19.01692
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。